Validación Empírica del Sistema Integrado de Información Financiera SIIF Nación II según el modelo de DeLone y McLean

En este trabajo se demuestra de manera empírica el éxito del Sistema Integrado de Información Financiera SIIF Nación II frente al modelo success system information de los reconocidos académicos norteamericanos DeLone y McLean, el cual da como resultado que el Sistema tiene falencias para ser exitoso, debido al incumplimiento de las dimensiones de calidad del sistema y satisfacción del usuario . Finalmente, se realizan unas recomendaciones para el mejoramiento del Sistema a la luz de la teoría de la administración pública y se realiza la salvedad que para realizar una validación del Sistema más coherente, se debe esperar el final de la vigencia 2012, como año base para determinar en una fase inicial del éxito del sistema

Flexible organizational structure for the Central Administrative and Accounting (CENAC) army engineers national Colombia

El presente trabajo de investigación basa su contenido en la formulación de una propuesta organizacional flexible para la Central administrativa y contable (CENAC) de ingenieros del Ejército Nacional de Colombia en la cuidad de Bogotá, organización dedicada a la defensa y seguridad del territorio nacional colombiano. A través de la identificación de la situación actual de la central administrativa y contable de ingenieros del Ejército nacional, se hizo necesaria la presentación de una estructura organizativa que permita mitigar la generación de desequilibrios administrativos que se han venido presentando desde la formación de estas nuevas centrales. Por medio de un diagnóstico de la estructura actual utilizada y una identificación de las fortalezas y debilidades del personal, en cuanto a perfiles cargos y funciones, fue posible determinar la estructura organizacional flexible adecuada para el CENAC ingenieros de la cuidad de Bogotá, que abarco no solo el organigrama apropiado, sino el personal con sus respectivos perfiles, cargos y funciones necesarios para el correcto funcionamiento de dicha estructura. Se espera que por medio de esta propuesta la central contable y administrativa de ingenieros ponga en práctica esta estructura como estrategia organizacional continua, para así cumplir con su objetivo de fortalecer los quehaceres administrativos del Ejercito Nacional de Colombia.This research bases in the formulation of a flexible organizational proposal for the administrative and accounting Central (CENAC) of the National Army of Colombia in the city of Bogotá, an organization dedicated to the defense and security of the Colombian national territory. Through the identification of the current status of the administrative and financial center of the national army, the presentation of an organizational structure that allows generating administrative mitigate imbalances that have been occurring since the formation of these new plants became necessary. Through an analysis of the current structure used and an identification of the strengths and weaknesses of staff profiles regarding positions and functions, it was possible to present a proposal for a suitable flexible organizational structure for CENAC of the city of Bogotá, covering not only the proper organization, but the staff with their respective profiles, duties and functions necessary for the proper functioning of this structure. It is hoped that through this proposed accounting and administrative central implement this structure as continuous organizational strategy, in order to meet its objective of strengthening the administrative tasks of the National Army of Colombia

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.

BACKGROUND: The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might be curtailed by vaccination. We assessed the safety, reactogenicity, and immunogenicity of a viral vectored coronavirus vaccine that expresses the spike protein of SARS-CoV-2. METHODS: We did a phase 1/2, single-blind, randomised controlled trial in five trial sites in the UK of a chimpanzee adenovirus-vectored vaccine (ChAdOx1 nCoV-19) expressing the SARS-CoV-2 spike protein compared with a meningococcal conjugate vaccine (MenACWY) as control. Healthy adults aged 18-55 years with no history of laboratory confirmed SARS-CoV-2 infection or of COVID-19-like symptoms were randomly assigned (1:1) to receive ChAdOx1 nCoV-19 at a dose of 5 × 1010 viral particles or MenACWY as a single intramuscular injection. A protocol amendment in two of the five sites allowed prophylactic paracetamol to be administered before vaccination. Ten participants assigned to a non-randomised, unblinded ChAdOx1 nCoV-19 prime-boost group received a two-dose schedule, with the booster vaccine administered 28 days after the first dose. Humoral responses at baseline and following vaccination were assessed using a standardised total IgG ELISA against trimeric SARS-CoV-2 spike protein, a muliplexed immunoassay, three live SARS-CoV-2 neutralisation assays (a 50% plaque reduction neutralisation assay [PRNT50]; a microneutralisation assay [MNA50, MNA80, and MNA90]; and Marburg VN), and a pseudovirus neutralisation assay. Cellular responses were assessed using an ex-vivo interferon-γ enzyme-linked immunospot assay. The co-primary outcomes are to assess efficacy, as measured by cases of symptomatic virologically confirmed COVID-19, and safety, as measured by the occurrence of serious adverse events. Analyses were done by group allocation in participants who received the vaccine. Safety was assessed over 28 days after vaccination. Here, we report the preliminary findings on safety, reactogenicity, and cellular and humoral immune responses. The study is ongoing, and was registered at ISRCTN, 15281137, and ClinicalTrials.gov, NCT04324606. FINDINGS: Between April 23 and May 21, 2020, 1077 participants were enrolled and assigned to receive either ChAdOx1 nCoV-19 (n=543) or MenACWY (n=534), ten of whom were enrolled in the non-randomised ChAdOx1 nCoV-19 prime-boost group. Local and systemic reactions were more common in the ChAdOx1 nCoV-19 group and many were reduced by use of prophylactic paracetamol, including pain, feeling feverish, chills, muscle ache, headache, and malaise (all p<0·05). There were no serious adverse events related to ChAdOx1 nCoV-19. In the ChAdOx1 nCoV-19 group, spike-specific T-cell responses peaked on day 14 (median 856 spot-forming cells per million peripheral blood mononuclear cells, IQR 493-1802; n=43). Anti-spike IgG responses rose by day 28 (median 157 ELISA units [EU], 96-317; n=127), and were boosted following a second dose (639 EU, 360-792; n=10). Neutralising antibody responses against SARS-CoV-2 were detected in 32 (91%) of 35 participants after a single dose when measured in MNA80 and in 35 (100%) participants when measured in PRNT50. After a booster dose, all participants had neutralising activity (nine of nine in MNA80 at day 42 and ten of ten in Marburg VN on day 56). Neutralising antibody responses correlated strongly with antibody levels measured by ELISA (R2=0·67 by Marburg VN; p<0·001). INTERPRETATION: ChAdOx1 nCoV-19 showed an acceptable safety profile, and homologous boosting increased antibody responses. These results, together with the induction of both humoral and cellular immune responses, support large-scale evaluation of this candidate vaccine in an ongoing phase 3 programme. FUNDING: UK Research and Innovation, Coalition for Epidemic Preparedness Innovations, National Institute for Health Research (NIHR), NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and the German Center for Infection Research (DZIF), Partner site Gießen-Marburg-Langen